Intellia's Lonvo-z Achieves 87% Attack Reduction in Phase 3; BLA Rolling, H1 2027 Launch Targeted
Summary
Intellia Therapeutics announced strong additional Phase 3 results for its gene-editing therapy, lonvo-z, demonstrating an 87% reduction in mean monthly attacks compared to placebo. This follows the initial positive Phase 3 results reported in April and further positive data on June 13th, with an 8-K filed today providing these details. The highly effective data, combined with the initiation of a rolling Biologics License Application (BLA) with the FDA and a targeted U.S. launch in H1 2027, significantly de-risks the drug and provides a clear path to market. This is a major step towards commercialization for a key pipeline asset. Investors will now focus on the BLA submission timeline and regulatory approval process.
At the time of this announcement, NTLA was trading at $12.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $7.95 to $28.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.